Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    15470214 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: < 15% risk of + LN;   Radiation: > 15% risk of + LN
2 Recruiting Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Cabozantinib;   Drug: Docetaxel;   Drug: Prednisone
3 Recruiting F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
Condition: Castration-resistant Prostate Cancer
Intervention: Device: F-Choline-PET
4 Completed S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Drug: docetaxel;   Drug: estramustine;   Drug: mitoxantrone;   Drug: prednisone

Indicates status has not been verified in more than two years